enGene (NASDAQ:ENGN) Receives “Sell (D-)” Rating from Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of enGene (NASDAQ:ENGN) in a research note published on Tuesday morning,Weiss Ratings reports.

Several other brokerages have also issued reports on ENGN. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of enGene in a research report on Monday, September 8th. Morgan Stanley decreased their target price on enGene from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.50.

enGene Price Performance

Shares of NASDAQ:ENGN opened at $8.81 on Tuesday. The company has a current ratio of 10.34, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09. The stock’s fifty day simple moving average is $5.68 and its two-hundred day simple moving average is $4.42. enGene has a 1-year low of $2.65 and a 1-year high of $11.00. The stock has a market cap of $450.98 million, a PE ratio of -4.64 and a beta of -0.27.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, September 11th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, analysts forecast that enGene will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On enGene

Several large investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co purchased a new stake in enGene in the 2nd quarter worth about $38,000. Affinity Asset Advisors LLC purchased a new stake in enGene in the 2nd quarter worth about $280,000. Cresset Asset Management LLC purchased a new stake in enGene in the 2nd quarter worth about $36,000. Adage Capital Partners GP L.L.C. increased its holdings in enGene by 2.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock worth $7,041,000 after acquiring an additional 41,874 shares during the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in enGene in the 1st quarter worth about $107,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.